Keywords: Wet-AMD, Market shares, Europe, Novartis, Kucentis, Roche, Avastin, Bayer, Eylea, Decision Resources

Novartis' Lucentis captures two-thirds of wet-AMD patient share in Europe

Article | 28 November 2012

Retinal specialists in the EU5 (France, Germany, Italy, Spain and the UK) treat 66% of intravitreal-pharmaceutically-treated wet age-related macular degeneration (AMD) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Novartis

Roche

Bayer

Go to company listing

Related Drugs

Avastin

Lucentis

Eylea

Go to drug listing